• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Budget Impact Analysis Of Biosimilar Infliximab For The Treatment Of Crohn's Disease In Six Central Eastern European Countries.

作者信息

Brodszky V, Gulacsi L, Balogh O, Baji P, Rencz F, Péntek M

机构信息

Corvinus University of Budapest, Budapest, Hungary.

出版信息

Value Health. 2014 Nov;17(7):A364. doi: 10.1016/j.jval.2014.08.805. Epub 2014 Oct 26.

DOI:10.1016/j.jval.2014.08.805
PMID:27200752
Abstract
摘要

相似文献

1
Budget Impact Analysis Of Biosimilar Infliximab For The Treatment Of Crohn's Disease In Six Central Eastern European Countries.生物类似药英夫利昔单抗治疗中东欧六个国家克罗恩病的预算影响分析
Value Health. 2014 Nov;17(7):A364. doi: 10.1016/j.jval.2014.08.805. Epub 2014 Oct 26.
2
A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.保加利亚、捷克共和国、匈牙利、波兰、罗马尼亚和斯洛伐克克罗恩病中生物类似药英夫利昔单抗的预算影响模型
Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119-25. doi: 10.1586/14737167.2015.1067142. Epub 2015 Jul 10.
3
Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.英夫利昔单抗在儿童早期而非晚期克罗恩病中的反应持续时间延长。
Am J Gastroenterol. 2000 Nov;95(11):3189-94. doi: 10.1111/j.1572-0241.2000.03263.x.
4
Budget Impact Analysis of Introducing Biosimilar Infliximab for the Treatment of Auto Immune Disorders In Five European Countries.在五个欧洲国家引入生物类似药英夫利昔单抗治疗自身免疫性疾病的预算影响分析
Value Health. 2014 Nov;17(7):A525. doi: 10.1016/j.jval.2014.08.1655. Epub 2014 Oct 26.
5
Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?英夫利昔单抗输注会影响克罗恩病肛周瘘管的手术治疗结果吗？
Dis Colon Rectum. 2007 Nov;50(11):1754-60. doi: 10.1007/s10350-007-9077-3. Epub 2007 Sep 27.
6
Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.克罗恩病中反应丧失及英夫利昔单抗剂量强化需求：一项综述
Am J Gastroenterol. 2009 Mar;104(3):760-7. doi: 10.1038/ajg.2008.88. Epub 2009 Jan 27.
7
Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.英夫利昔单抗可治愈克罗恩病患儿的肠道炎性病变并恢复其生长。
Dig Liver Dis. 2004 May;36(5):342-7. doi: 10.1016/j.dld.2003.12.014.
8
Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.肛瘘性肛门克罗恩病：手术联合英夫利昔单抗治疗的结果
Dis Colon Rectum. 2006 Dec;49(12):1837-41. doi: 10.1007/s10350-006-0656-5.
9
Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.英夫利昔单抗治疗克罗恩病：疗效、安全性及药物经济学
Can J Clin Pharmacol. 2001 Winter;8(4):188-98.
10
Infliximab and surgical treatment of complex anal Crohn's disease.英夫利昔单抗联合手术治疗复杂肛门克罗恩病。
Colorectal Dis. 2012 Aug;14(8):972-6. doi: 10.1111/j.1463-1318.2011.02811.x.

引用本文的文献

1
Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.韩国接受生物类似药及其对类风湿关节炎患者治疗的经济影响。
J Korean Med Sci. 2021 May 24;36(20):e143. doi: 10.3346/jkms.2021.36.e143.
2
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.评估生物类似药的价值：预算影响分析的作用综述。
Pharmacoeconomics. 2017 Oct;35(10):1047-1062. doi: 10.1007/s40273-017-0529-x.
3
Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
中东欧国家生物类似药的定价与报销
Front Pharmacol. 2017 Jun 8;8:288. doi: 10.3389/fphar.2017.00288. eCollection 2017.
4
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.用于治疗慢性炎症性疾病的生物类似药：已发表证据的系统评价
BioDrugs. 2016 Dec;30(6):525-570. doi: 10.1007/s40259-016-0201-6.
5
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence.跨治疗领域的单克隆抗体和融合蛋白生物类似药：已发表证据的系统评价
BioDrugs. 2016 Dec;30(6):489-523. doi: 10.1007/s40259-016-0199-9.